Biocon quarterly (Q1) profit up 12.49%
The company had posted net profit of Rs 70.05 crore for the April-June quarter of the 2011-12 fiscal, Biocon said in a statement.
Consolidated total income of the company rose to Rs 576.68 crore in Q1, from Rs 443.48 crore for the year-ago period.
Commenting on the results, Biocon Chairman and MD Kiran Mazumdar-Shaw said: "I am pleased to report that we have seen strong performances across all our business verticals and this reflects the success of our segmented business model".
During the first quarter of the current financial year, biopharma business of the major grew 23 per cent YoY. Branded formulations also registered robust growth of 52 per cent from the same quarter year ago led by oncology, comprehensive care and diabetology, the company said.
The company continued its engagement with potential partners for its licensable assets in 105 and Itolizumab.
"On the licensing front, we are in discussions for several advancing research programmes. We are hopeful that many of these will be realised going forward. This will endorse our R&D-led value creation strategy," Mazumdar-Shaw said.
The 52-week data from the Phase III trial in Psoriasis confirms the achievement of primary endpoint and multiple secondary endpoints , Biocon said.
"We intend to file for regulatory approval and marketing authorisation for the treatment of Psoriasis, for this molecule in the Indian market shortly," it added.
Be the first to comment.